Globeimmune Cash on Hand 2013-2016 | GBIM
Globeimmune cash on hand from 2013 to 2016. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Globeimmune Annual Cash on Hand
(Millions of US $) |
| 2015 |
$10 |
| 2014 |
$17 |
| 2013 |
$6 |
| 2012 |
$0 |
Globeimmune Quarterly Cash on Hand
(Millions of US $) |
| 2016-03-31 |
$9 |
| 2015-12-31 |
$10 |
| 2015-09-30 |
$11 |
| 2015-06-30 |
$12 |
| 2015-03-31 |
$14 |
| 2014-12-31 |
$17 |
| 2014-09-30 |
$19 |
| 2014-06-30 |
$6 |
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
GlobeImmune, Inc. is a biopharmaceutical company. It is focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen (R) platform. The Company's products under development includes GI-5005, a product for the treatment of chronic hepatitis C infection; and GI-4000 for pancreas, non-small cell lung, colorectal, and other cancers. GlobeImmune, Inc. is based in Louisville, Colorado.
|
